LifeSci Venture Partners
Edit

LifeSci Venture Partners

https://www.lifesciventure.com
Last activity: 22.04.2025
Active
Invests in categories: HealthTechMedtechDrugBioTechTechnologyCareResearchScienceProductWearables
Formed in 2017, LifeSci Venture Partners is the early stage investing arm of LifeSci Partners, a unique life sciences and healthcare consultancy formed in 2010.

Our investment principals have broad-ranging life sciences experience including public and private investing, deal structuring, investment banking, equity capital markets, equity research, and bench research - both basic science and applied.

Across our affiliated business units, we employ more than 120 experienced investment and science professionals, including 20+ PhDs and MDs in New York City, Boston, Philadelphia, London, Geneva, Paris and Tel Aviv. We make the broad resources and expertise of our team available to our portfolio companies in helping them execute on their business plans and maximize shareholder value.
News
19
Portfolio
15
Mentions
2
Location: United States, New York
Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 15

DateNameWebsiteTotal RaisedLocation
21.08.2020Science 37science37.com$135.5MUnited Sta...
-Novus Ther...novustherapeutics.com--
-Attune Pha...attunepharma.com$23M-
-Metacrinemetacrine.com$123MUnited Sta...
-Orasisorasis-pharma.com$121M-
-Athira Pha...athira.com$289MUnited Sta...
-Allakos In...allakos.com$292MUnited Sta...
-Rocket Pha...rocketpharma.com-United Sta...
-Biolinqbiolinq.me$14.75MUnited Sta...
-Beta Bioni...betabionics.com$280MUnited Sta...
Show more

News 19

DateTitleDescription
20.08.2020Science37 Raises $40million to extend its leadership in the decentralized CRO space-
05.06.2020UCB Acquires Engage Therapeutics-
05.06.2020Athira Pharma Closes $85 Million Series B Financing-
27.04.2020Erasca Raises $200 Million Series B Financing-
19.06.2019Akero Therapeutics Announces Pricing of Initial Public Offering-
21.05.2019Cala Health Raises $50 Million Series C Funding-
23.01.2019Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN249 for the Treatment of HAE-
11.01.2019Beta Bionics Announces Final Closing of Its $63 Million Series B Financing-
12.12.2018Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases-
24.07.2018Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares-
Show more

Mentions in press and media 2

DateTitleDescription
23.04.2025Biolinq's $100 Million Leap: A New Era for Diabetes ManagementIn the world of health technology, innovation is the lifeblood. Biolinq, a California-based company, has just injected a hefty $100 million into its vision for the future of diabetes management. This Series C funding round, led by Alpha Wav...
22.04.2025Biolinq Raises $100M to Expand Biowearable Platform for Metabolic HealthWhat You Should Know: – Biolinq, a healthcare technology company focused on developing precision multi-analyte biosensors to improve metabolic health raises $100M in Series C financing round led by Alpha Wave Ventures, with participation fr...

Reviews 0

Sign up to leave a review

Sign up Log In